WO2008015383A2 - Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer - Google Patents
Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer Download PDFInfo
- Publication number
- WO2008015383A2 WO2008015383A2 PCT/GB2007/002755 GB2007002755W WO2008015383A2 WO 2008015383 A2 WO2008015383 A2 WO 2008015383A2 GB 2007002755 W GB2007002755 W GB 2007002755W WO 2008015383 A2 WO2008015383 A2 WO 2008015383A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bmp
- cells
- prostate cancer
- polypeptide
- breast
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 50
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 50
- 210000000481 breast Anatomy 0.000 title claims abstract description 50
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 37
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 37
- 238000011275 oncology therapy Methods 0.000 title 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 claims abstract description 137
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 claims abstract description 87
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims abstract description 80
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 210000002307 prostate Anatomy 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 11
- 230000001093 anti-cancer Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 210000005267 prostate cell Anatomy 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 162
- 102000037280 Growth Differentiation Factor 2 Human genes 0.000 description 122
- 206010028980 Neoplasm Diseases 0.000 description 32
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 27
- 108050008407 Bone morphogenetic protein receptor type-2 Proteins 0.000 description 27
- 102100040853 PRKC apoptosis WT1 regulator protein Human genes 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 26
- 101710162991 PRKC apoptosis WT1 regulator protein Proteins 0.000 description 25
- 230000006907 apoptotic process Effects 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 19
- 238000010186 staining Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 230000010261 cell growth Effects 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000002018 overexpression Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 102000053642 Catalytic RNA Human genes 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 8
- 108700019146 Transgenes Proteins 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 108091092562 ribozyme Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 5
- 238000002701 cell growth assay Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000003125 immunofluorescent labeling Methods 0.000 description 5
- 239000013600 plasmid vector Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000009758 senescence Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 102000046041 human GDF2 Human genes 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 3
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 108010023082 activin A Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000035289 cell-matrix adhesion Effects 0.000 description 3
- 210000003570 cell-matrix junction Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 2
- 101000613565 Homo sapiens PRKC apoptosis WT1 regulator protein Proteins 0.000 description 2
- 102100036186 Importin subunit alpha-5 Human genes 0.000 description 2
- 101710118220 Importin subunit alpha-5 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 2
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- TZWIIMGBPYFURE-UHFFFAOYSA-N [(4-chlorophenyl)sulfonyl-[(2-methylpropan-2-yl)oxycarbonyl]amino] acetate Chemical compound CC(C)(C)OC(=O)N(OC(=O)C)S(=O)(=O)C1=CC=C(Cl)C=C1 TZWIIMGBPYFURE-UHFFFAOYSA-N 0.000 description 2
- GWYBSWWLKXEDLB-UHFFFAOYSA-N [acetyl-(4-chlorophenyl)sulfonylamino] acetate Chemical compound CC(=O)ON(C(C)=O)S(=O)(=O)C1=CC=C(Cl)C=C1 GWYBSWWLKXEDLB-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- 102000052974 human BMP10 Human genes 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 108010011989 karyopherin alpha 2 Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- 101710173011 Activin receptor type-1B Proteins 0.000 description 1
- 108090000663 Annexin A1 Proteins 0.000 description 1
- 102100040006 Annexin A1 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000007808 Cell invasion assay Methods 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 description 1
- 244000309469 Human enteric coronavirus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012162 RNA isolation reagent Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to two novel agents, BMP-9/BMP-10, for treating breast or prostate cancer; vectors adapted to transform or transfect breast or prostate tissue which vectors are designed to express either, or both, BMP-9 and BMP-10; cell lines which have been transformed or transfected so as to express native or recombinant BMP-9 and/or BMP-10; a method for the recombinant production of BMP-9 and/or BMP-10; and methods for treating breast or prostate cancer comprising exposing breast or prostate cancer tissue to BMP-9 and/or BMP-10.
- Bone morphgenesis proteins are a protein family that belongs to the TGF ⁇ (transforming growth factor beta) superfamily. BMPs are widely involved in the regulation of cell functions including cell growth and apopotosis. More than 20 BMPs have been reported so far. The proteins are also important in embryo development and tissue regeneration. Some of the BMPs are also known to be important players in cancer. For example, BMP-2, BMP-6 and BMP-7 have been shown to be aberrantly expressed in human cancers and that raised levels of the proteins either in the circulation or in tumours are associated with progression and spread of cancer.
- TGF ⁇ transforming growth factor beta
- BMPs exert their effects through a heteromeric receptor complex, which consists of two types of serine-threonine kinase transmembrane receptors.
- the Type-I receptors include BMP receptor type IA (BMPR-IA) 1 type IB (BMPR-IB), Activin receptor-like kinase-1 (ALK-1), ALK-4, ALK-5 and activin A receptor type I (ActRI).
- the Type-ll receptors include BMP receptor type Il (BMPR-II), activin A receptor type HA (ActRII) and activin A receptor type MB (ActRIIB). Upon binding to BMP ligands, the Type-ll receptors then phosphorylates the Type-I receptors.
- R-Smads pathway-restricted Smads
- Smadsi pathway-restricted Smads
- BMP-9 and BMP-10 have a very strong anti-cancer functions. This is in clear contrast to other BMPs of which high levels are most associated with pro-cancer actions.
- BMP-9 otherwise known as GDF2 (Growth and Differentiation Factor-2) was first found in liver cells (Celeste et al 1994) and the major source is Kupffer, Stellate and endothelial cells (Miller et al 2000). In embryos, BMP-9 was highly expressed in neural tissues and therefore has been indicated in the development of nervous system. In bones, BMP-9 was able to induce differentiation of osteoclast. BMP-10, discovered in 1999 (Neuhaus et al 1999), is known to be expressed at good levels in heart and lung and has also been indicated in embryo development such as heart. Statements of Invention
- Our invention concerns the role of BMP-9 and/or BMP-10 in breast or prostate cancer and more particularly the inhibitory role of BMP-9 and/or BMP- 10 in breast or prostate cancer.
- an anti- cancer agent for treating breast or prostate cancer comprising a nucleic acid molecule encoding BMP-9, as shown in Figure 9, or a homologue thereof, or a nucleic acid molecule that hybridises to the sequence shown in Figure 9 under stringent conditions.
- an anticancer agent for treating breast or prostate cancer comprising a nucleic acid molecule encoding BMP-10, as shown in Figure 10, or a homologue thereof, or a nucleic acid molecule that hybridises to the sequence shown in Figure 10 under stringent conditions.
- Reference herein to stringent conditions includes reference to either increasing the temperature of incubation to above 25 0 C and more preferably above 5O 0 C and more preferably still up to 65 0 C and/or washing the annealed molecules using a salt solution having an ionic strength of 1.0N sodium chloride - 0.02N sodium chloride, and most preferably 0.5N sodium chloride - 0.02N sodium chloride and more preferably still 0.1 N sodium chloride to 0.02N sodium chloride.
- polypeptide that has anti-cancer activity in treating breast or prostate cancer comprising the polypeptide BMP-9 as shown in Figure 9, or a homologue thereof, or a fragment thereof which has BMP-9 anti-cancer activity.
- a polypeptide that has anti-cancer activity in treating breast or prostate cancer comprising the polypeptide BMP-10 as shown in Figure 10, or a homologue thereof, or a fragment thereof which has BMP-10 anti-cancer activity.
- a nucleic acid molecule encoding BMP-9 and/or BMP-10 for treating breast or prostate cancer.
- BMP-9 or BMP-10 polypeptide for treating breast or prostate cancer.
- a medicament comprising either the nucleic acid molecule encoding BMP-9 and/or BMP-10, and/or the corresponding BMP-9 and/or BMP-10 polypeptide.
- the medicament of the invention is most suitable for treating breast or prostate cancer.
- the medicament is formulated with a suitable excipient, carrier or emollient.
- a method for treating breast or prostate cancer comprising administering to an individual to be treated a medically effective amount of BMP-9 and/or BMP-10.
- a method for treating breast or prostate cancer comprising increasing cellular levels of either exogenous or endogenous BMP-9 and/or BMP-10 in breast or prostate cells.
- Reference herein to the exogenous increase in cellular levels of BMP-9 and/or BMP-10 includes reference to: introducing into breast and/or prostate cells either externally manufactured BMP-9 and/or BMP-10 polypeptide; or introducing means for increasing the said cells production of BMP-9 and/or BMP-10 by, for example, introducing a copy of, or increasing the number of copies of, the BMP-9 and/or BMP-10 gene.
- Reference herein to the endogenous increase in cellular levels of BMP-9 and/or BMP-10 polypeptide includes introducing into breast and/or prostate cells means that enables the breast or prostate cells to increase native production of BMP-9 and/or BMP-10 polypeptide, for example, suitable means include supplementing the cells' manufacturing machinery to provide for the increased production of BMP-9 and/or BMP-10 such as by increasing the effectiveness or activity of the promoter(s) controlling the expression of BMP-9 and/or BMP-10 gene whereby the overall production of BMP-9 and/or BMP-10 is increased, or, additionally or alternatively, supplementing the cells' other cellular protein production pathways whereby the amount of BMP-9 and/or BMP-10 produced is increased.
- suitable means include supplementing the cells' manufacturing machinery to provide for the increased production of BMP-9 and/or BMP-10 such as by increasing the effectiveness or activity of the promoter(s) controlling the expression of BMP-9 and/or BMP-10 gene whereby the overall production of BMP-9 and/or BMP-10 is increased, or, additionally or
- a vector adapted to transfect or transform breast or prostate cells wherein said vector includes:
- At least one over-expressing or constitutively active promoter which is either coupled to the BMP-9 and/or BMP-10 gene of part 1. and/or which is designed for insertion into a genome upstream of the native BMP-9 and/or BMP- 10 gene of said breast or prostate cells; whereby transfection or transformation of said cells with said vector results in the enhanced expression of BMP-9 and/or BMP-10.
- a cell line which has been transfected or transformed with a vector encoding at least one copy of the gene for BMP-9 and/or BMP-10 or as described herein.
- a 3T3 cell line or a PC-3 cell line, or a DU145 cell line, or a MDA231 cell line or a T24 cell line which has been transfected or transformed so as to recombinantly express BMP-9 and/or BMP-10.
- BMP-9 and/or BMP-10 which has been manufactured by a host cell that has been transfected or transformed with a vector described herein.
- a method for manufacturing recombinant BMP-9 and/or BMP-10 which method comprises:
- said vector further includes a suitable secretion signal whereby once BMP-9 and/or BMP-10 polypeptide has been produced it is processed through the cell's machinery for secretion and therefore the secreted polypeptide can be harvested from the extra cellular medium.
- BMP-9 and/or BMP-10 to treat breast or prostate cancer.
- BMP-9 and/or BMP-10 in the manufacture of a medicament to treat breast or prostate cancer.
- a BMP-9 or BMP-10 receptor or downstream signalling molecule such as Par-4 or Smad- 1 , or Smad-5 or Smad-8, or an agonist or enhancer of any of the afore molecules for use in treating breast or prostate cancer.
- FIG 1 shows Figure-1. Staining of BMP-9 in mammary (left two panels) and prostate (right two panels) tissues (normal (left) and tumour (right) tissues are shown in the respective tissue type). Normal epithelial cells stained positively for BMP-9. The protein staining, however, was lost in tumour cells (right).
- FIG 2 shows Staining of BMP-10 in mammary (left two panels) and prostate (right two panels) tissues (normal (left) and tumour (right) tissues are shown in the respective tissue type). Normal epithelial cells stained positively for BMP-10. The protein staining, however, was lost in tumour cells (right).
- the top panel shows correlation between BMP transcripts and prognosis, in which NPI-1 indicating patients with good prognosis, NPI-2 with moderate and NPI-3 with a poor prognosis. Patients with a poor prognosis had significantly lower levels of BMP-10;
- Figure 4 shows expression of BMP-9 and BMP-10 in cancer cells, as revealed by RT-PCR.
- FIG. 5 shows the construction and generation of BMP-9 (A and B) and BMP-10 (C and D) expression vector.
- a and C are selected from transformed E. CoIi.
- C and D are purified, respective, plasmids;
- Figure 6 shows the establishment of BMP-9 in PC-3 prostate cancer cells (top) and BMP-9 and BMP-10 (bottom) in MDA MB 231 breast cancer cells. Shown are mRNA from PC-3 cells (top), and mRNA from MDA MB 231 cells (bottom);
- Figure 6A shows the amount of BMP-9 protein produced in PC-3 cells
- Figure 7 shows protein expression in transfected cancer and other mammalian lines.
- Successful cell lines were established in 3T3 (fibroblast) for BMP-9; 3T3 (fibroblast), PC-3 (prostate) and T24 (bladder) cells for BMP-10, (HECV is an endothelial cell line and DU14 is a prostate cell line);
- Figure 8 shows over-expression of BMP-9 and BMP-10 in cancer cells (MDA MB-231 breast cancer, PC-3 prostate cancer and DU145 prostate cancer) resulted in a slower growth and reduced invasion;
- Figure 9 shows the impact of BMP-9 on the ability of prostate cancer cells to adhere to the Extracellular matrix
- Figure 10 shows the effect of BMP-9 over-expression on cellular motility using an in vitro migration assay
- FIG 11 shows BMP-9 induces apoptosis in PC-3 cells via Par-4.
- A overexpression of BMP-9 induces apoptosis in PC-3 cells using a flow cytometry.
- the percentage of the apoptotic cells in pc-3 BMP"9exp cells is 29.4% (top), which is remarkably higher than the 0.45% of pc-3 pEF/His cells (middle) and 5.00% of PC-S ⁇ (bottom).
- B top panel shows an increase of Par-4 transcripts in PC-3BMP-9exp cells using RT-PCR 1 while the lower panel of B shows the elevated level of Par-4 protein in PC-3 by over-expression of BMP-9 using Western blot analysis.
- Figure 12 shows Both BMPR-1 B and BMPR-2 mediate inhibitory effects on cell growth of prostate cancer cells.
- A knockdown of BMPR-IB and BMPR-II mRNA in PC-3 cells by the ribozyme transgenes was verified using RT-PCR.
- the gene transcripts of BMPR-IB were diminished in the pc-3 ⁇ BMPR IB cells by the ribozyme transgenes (top).
- the PCR reactions were performed 30 cycles.
- the mRNA level of BMPR-II was also markedly reduced in the pc-3 ⁇ BMPR" ", compared with the PC-S ⁇ and pc-3 pEF/His (bottom).
- the ribozyme transgenes reduced the protein production of BMPR-IB and BMPR-II in PC-3 cells using western blot analysis.
- the protein production of BMPR-IB was eliminated in the pC 3 ⁇ BMPR-IB cel
- the cell growth rate at day 4 is 239.3% ⁇ 30.7% of PC-3 m cells and 209.9% ⁇ 26.9% of pc _ 3 pEF/His ce
- The' growth rate was calculated as a percentage using the absorbance of day 1 as a baseline.
- Figure 13 shows BMP-9 signals through a Smad-dependent pathway in PC-3 cells.
- A effects of rh-BMP-9 on in vitro cell growth of PC-3 cells was examined using the in vitro cell growth assay. The cell growth of PC-3 cells were reduced by the exposure of rh-BMP-9 at 50ng/ml. Error bars are standard deviations. * p ⁇ 0.05 vs control.
- B rh-BMP-9 (20ng/ml) induced apoptosis in PC- 3 cells using flow cytometry. The percentage of cells in exposure to rh-BMP-9 undergoing apoptosis is 16.88%, which is higher than the control (7.73%).
- C BMP-9 signal through Smad dependent pathway in PC-3 cells.
- BMPR-IB top
- BMPR-II middle
- D lmmunofluorescent staining of phosphorylated Smad-1 by BMP-9 in PC-3 cells.
- Figure 14 shows the nucleic acid sequence and corresponding amino acid sequence of BMP-9.
- Figure 15 shows the nucleic acid sequence and the corresponding amino acid sequence of BMP-10. Materials and Methods Human tumour tissues
- PC-3 ECACC, European Collection of Animal Cell Culture, Salisbury, UK
- DU-145, LNCapFGC, CA-HPV10 and PZ-HPV-7 ATCC, American Type Culture Collection, Mannasas, Virginia
- Polyclonal goat anti-BMP-9, monoclonal mouse anti-actin, polyclonal goat anti-phospho Smad 1 and monoclonal mouse anti-Par-4 were obtained from Santa Cruz Biotechnology (Santa Cruz, California, USA).
- Other reagents or kits were obtained from Sigma- Aldrich, Poole, United Kingdom. Immuno-histochemical Staining of Breast and prostate tissue sections
- Frozen sections of normal and tumours were cut at a thickness of 6 ⁇ m using a cryostat.
- the sections were mounted on super frost plus microscope slides, air-dried and then fixed in a mixture of 50% Acetone and 50% methanol.
- the sections were then placed in "Optimax" wash buffer for 5 -10 minutes to rehydrate.
- Sections were incubated for 20 minutes in a 0.6% BSA blocking solution and probed with the primary antibodies. Following extensive washings, sections were incubated for 30 minutes in the secondary biotinylated antibody (Multilink Swine anti-goat/mouse/rabbit immunoglobulin, Dako Inc.). Following washings, the Avidin Biotin Complex (Vector Laboratories) was then applied to the sections, followed by extensive washing steps.
- Diamino benzidine chromogen (Vector Labs) was then added to the sections, and incubated in the dark for 5 minutes. Sections were then counter stained in Gill's Haematoxylin and dehydrated in ascending grades of methanol before clearing in xylene and mounting under a cover slip.
- Full length cDNA for the respective BMP were cleaned by gel separated and extraction, T-A cloned into an mammalian expression vector, pEF6/TOPO, which were subsequently used to transform the TOPO10 E. CoI.
- Discrete bacterial colonies were screened for the presence of the coding sequence and direction of the inserts. Positive colonies were isolated, amplified, and plasmids subsequently extracted using a plasmid extraction kit. Following verification of the plasmids, purified plasmids were used to transfect breast and prostate cancer cell lines, followed by selection with blastidicin containing medium.
- the first strand cDNA was synthesized from RNA isolated from normal human tissues using a DuraScriptTM RT-PCR kit s. PCR was then used to amplify the coding sequence of full-length human BMP-9 using the Extensor Hi-Fidelity PCR master mix (ABgene Ltd., Epsom, UK). The sequences of primers are shown in Table 3.
- the verified BMP-9 insert was cloned into a mammalian expression plasmid vector (pEF/His TOPO TA plasmid vector, Invitrogen, Inc., Paisley, UK). The recombinant plasmid vectors were transformed into chemically competent TOP10 E. CoIi (Invitrogen, Inc., Paisley, UK), and the colonies were then analyzed. Colonies carrying correct recombinant plasmids were amplified, and the BMP-9 recombinant plasmids were then extracted
- Anti-human BMPR-IB and anti-human BMPR-II hammerhead ribozymes targeting were designed based on the secondary structure of the respective gene generated using Zuker's RNA mFold program (Zuker et al 2003).
- the ribozymes were individually cloned into a mammalian expression pEF6/V5-His- TOPO plasmid vector (Invitrogen Ltd., Paisley, UK). Ribozyme transgenes and control plasmid vectors were then transfected into PC-3 cells respectively. After up to 3 weeks selection using blasticidin, the transfectants were used in the current study.
- the protein concentration in cell lysates were determined using the DC Protein Assay kit (BIO-RAD) and an ELx ⁇ OO spectrophotometer (BIO-TEKTM). Equal amount of proteins were separated by sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE), and blotted onto nitrocellulose sheets. Proteins were then probed with the anti-BMP-9/10 antibody and peroxidase-conjugated secondary antibodies. Protein bands were visualized using the SupersignalTM West Dura system (Pierce Biotechnology, Inc., Rockford, IL 1 USA), and photographed using a UVITech imager (UVITech, Inc., Cambridge, UK).
- the plasmids thus generated were referred to as pEF6/BMP9Exp and pEF6/BMP10Exp.
- the cells generated were referred to as
- the BMP modified cancer cells were seeded in a 96 well plate at a density of 7,000 cells/well, and incubated at 37°C for up to 5 days. Cells were fixed and stained with Crystal violet. Absorbance was measured on a multiplate reader.
- Transwell chambers equipped with a 6.5mm diameter polycarbonate filter insert (pore size 8 ⁇ m)(Becton Dickinson, Labware, Oxford, UK) 1 were pre- coated with 50 ⁇ g/insert of solubilised tissue basement membrane, Matrigel (Collaborative Research Products, Bedford, Massachusetts, USA). 40,000 cancer cells were seeded into each insert and allowed to invade for 3 days. Following incubation, cells that had invaded through the basement membrane were fixed (4% formaldehyde), and then stained with crystal violet. For analysis, the cells were counted in 10 fields/insert (x40 magnification); to determine the mean number of invaded cancer cells.
- Cells were plated into a 96-well plate (2,500cells/well). Cell growth was assessed after a period of incubation (upto 5 days). Crystal violet was used to stain cells, and absorbance was determined at a wavelength of 540nm using a spectrophotometer (BIO-TEK, Elx800, UK).
- Transwell inserts with 8 ⁇ m pore size were coated with 50 ⁇ g Matrigel (BD MatrigelTM Basement Membrane Matrix) and air dried. The Matrigel was rehydrated before use. 20,000 cells were added to each well. After 96 hours cells that had migrated through the matrix to the other side of the insert were fixed in 4% formalin, stained with 0.5% (weight/volume) crystal violet and counted under a microscope.
- Matrigel BD MatrigelTM Basement Membrane Matrix
- 50,000 Cells were seeded into each well of a chamber slide and allowed to reach near confluence. The layer of cells was then scraped with a fine gauge needle. The movement of cells to close the wound was recorded using a time lapse video recorder and analyzed using the Optimas 6.0 motion analysis.
- PC-3 cells were seeded on glass chamber slide in a duplicated manner. Following 2 hours of incubation in serum free DMEM the cells were exposed to rh-BMP-9 (20ng), or serum free medium alone for 1 hour.
- the immunofluorescent staining of phosphorylated Smad-1 was performed using anti-Phosph-Smad1 antibody is 1 :50 from original, and the TRITC labelled anti-goat IgG was used at 1 :200, and then photographed.
- cancer cell lines had different pattern of expression of both BMP-9 and BMP-10.
- BMP-9 and BMP1- 10 BMP-9 and BMP-10 were amplified from normal human cDNA bank and cloned into a mammalian expression vector. Following screening ( Figure 5 A and C), plasmids were extracted and purified ( Figure-5 B and D) and used for electroporation.
- BMP-9 and BMP-10 over-expression resulted in death/senescence of cancer cells as well as CHO cells It was during the selection stage that we realised that over-expressing BMP-9 in CHO and PC-3 (prostate) and DU-145 (breast) results in cells rapidly developing cell senescence, and so we were unable to establish stably transfected cells. This suggests that BMP-9 triggers the cancer cells to terminal development, which eventually lead to death.
- Figure-8 shows the growth of cancer cells that have stable integration for BMP-9 and BMP-10. These cells were selected under extreme conditions, as most cells were dead in most experiments. ⁇
- pc3 BMP9exp cells showed a significantly reduced cellular migration, compared with the controls. A remarkable reduction of distance migrated was seen in these cells, 60 minutes after wounding. The average distance migrated over 90 minutes for pc-3 BMP'9exp cells was 17.22 ⁇ 3.61 ⁇ m, p ⁇ 0.05 vs both PC- ⁇ (32.47 ⁇ 2.98 ⁇ m) and pc-3 pEF/His (30.26 ⁇ 2.43 ⁇ m), as shown in Fig. 10.
- Prostate apoptosis response-4 (Par-4) has been demonstrated as being up-regulated in androgen-independent prostate cancer cells which were induced to undergo apoptosis (28-30).
- the PC-3 cells used in this study is androgen insensitive, and derived from bone metastasis of prostate cancer. Therefore, we hypothesised that Par-4 may be involved in the apoptosis induced by BMP-9.
- FIG. 11B shows an up-regulation in the mRNA level of Par-4 in p C _ 3 BMP - 9e x p ce
- An elevated protein level of Par-4 was shown in the pc-3 BMP"9exp cells (Fig. 11 B-lower panel).
- the immunocytochemical staining also demonstrated an increased Par-4 protein in pc-3 BMP"9exp cells which appeared to be more condensed in the nuclei of the cells (Fig. 11C). This phenomenon is further elucidated in the immunofluorescent staining of Par-4 (Fig. 11 D).
- Both BMP-9 and BMP-10 are expressed at lower levels in breast and prostate tumour tissues compared with normal tissues. The levels are particularly low in aggressive tumours. This suggests that loss of both BMPs are associated with an aggressive clinical condition in clinical cancer.
- the study has further shown that over-expressing BMP-9 and BMP-10 in cancer cells lead to unexpected slower growth; reduced migration, motility, invasion and adhesion; and finally senescence and apoptosis in cancer cells.
- Apoptosis is the key event for physiological growth control and regulation of tissue homeostasis.
- BMP-9 inhibited in vitro cell growth of prostate cancer cells. This was not related to necrotic cell death, as observed during the study. This has lead us to discover that apoptosis is potentially the underlying mechanism for the reduced rate of cell growth induced by BMP9.
- BMP-9 proapoptotic protein
- Par-4 is a proapoptotic protein, which was originally identified in prostate cancer cells undergoing apoptosis in response to ionomycin.
- Par-4 is involved in the apoptosis induced by tumor necrosis factor (TNF), doxorubicin, et ⁇ poside, UV irradiation, growth factor deprivation, and ionizing radiation.
- TNF tumor necrosis factor
- doxorubicin doxorubicin
- et ⁇ poside UV irradiation
- growth factor deprivation growth factor deprivation
- ionizing radiation ionizing radiation.
- Par-4 is involved in the apoptosis induced by BMP-9 in the PC-3 androgen insensitive prostate cancer cells (PC-3).
- BMP-9 and BMP-10 are therapeutic agents in cancers including breast and prostate cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne le rôle des protéines BMP-9 et/ou BMP-10 dans le traitement du cancer du sein ou de la prostate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0615129.4 | 2006-07-29 | ||
GBGB0615129.4A GB0615129D0 (en) | 2006-07-29 | 2006-07-29 | Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008015383A2 true WO2008015383A2 (fr) | 2008-02-07 |
WO2008015383A3 WO2008015383A3 (fr) | 2008-08-14 |
WO2008015383A8 WO2008015383A8 (fr) | 2009-07-16 |
Family
ID=37006438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/002755 WO2008015383A2 (fr) | 2006-07-29 | 2007-07-20 | Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0615129D0 (fr) |
WO (1) | WO2008015383A2 (fr) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009084739A1 (fr) * | 2007-12-28 | 2009-07-09 | Kyowa Hakko Kirin Co., Ltd. | Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp10 |
WO2009084738A1 (fr) * | 2007-12-28 | 2009-07-09 | Kyowa Hakko Kirin Co., Ltd. | Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp9 |
WO2013152213A1 (fr) * | 2012-04-06 | 2013-10-10 | Acceleron Pharma, Inc. | Méthodes et compositions pour l'augmentation des érythrocytes |
US8703694B2 (en) | 2009-06-08 | 2014-04-22 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
US8703927B2 (en) | 2008-08-14 | 2014-04-22 | Acceleron Pharma Inc. | Isolated nucleotide sequences encoding GDF traps |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
US8765663B2 (en) | 2009-01-13 | 2014-07-01 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
US9138459B2 (en) | 2004-07-23 | 2015-09-22 | Acceleron Pharma Inc. | ACTRIIB-FC polynucleotides, polypeptides, and compositions |
US9163075B2 (en) | 2005-11-23 | 2015-10-20 | Acceleron Pharma Inc. | Isolated polynucleotide that encodes an ActRIIa-Fc fusion polypeptide |
US9181533B2 (en) | 2009-06-12 | 2015-11-10 | Acceleron Pharma, Inc. | Truncated ACTRIIB-FC fusion protein |
US9353356B2 (en) | 2007-09-18 | 2016-05-31 | Acceleron Pharma Inc. | Activin-actriia antagonists for treating a follicle-stimulating horomone-secreting pituitary tumor |
US9399669B2 (en) | 2007-02-02 | 2016-07-26 | Acceleron Pharma Inc. | Variants derived from ActRIIB |
US9480742B2 (en) | 2005-11-23 | 2016-11-01 | Acceleron Pharma Inc. | Method of promoting bone growth by an anti-actriia antibody |
US9493556B2 (en) | 2010-11-08 | 2016-11-15 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
US9505813B2 (en) | 2008-08-14 | 2016-11-29 | Acceleron Pharma Inc. | Use of GDF traps to treat anemia |
US9526759B2 (en) | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
US9572865B2 (en) | 2005-11-23 | 2017-02-21 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating multiple myeloma |
WO2017046227A2 (fr) * | 2015-09-17 | 2017-03-23 | Histide Ag | Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique et ses utilisations |
WO2017046228A3 (fr) * | 2015-09-17 | 2017-06-29 | Histide Ag | Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique, et ses utilisations |
US9850298B2 (en) | 2014-06-13 | 2017-12-26 | Acceleron Pharma Inc. | Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide |
US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
US11471510B2 (en) | 2014-12-03 | 2022-10-18 | Celgene Corporation | Activin-ActRII antagonists and uses for treating anemia |
US11578110B2 (en) | 2015-08-25 | 2023-02-14 | Histide Ag | Compounds for inducing tissue formation and uses thereof |
WO2023069447A1 (fr) * | 2021-10-18 | 2023-04-27 | The Uab Research Foundation | Bmp9 ou agoniste de celui-ci et ses utilisations en rapport avec la réduction des métastases du cancer |
US11813308B2 (en) | 2014-10-09 | 2023-11-14 | Celgene Corporation | Treatment of cardiovascular disease using ActRII ligand traps |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1435243A2 (fr) * | 1998-11-13 | 2004-07-07 | Curis, Inc. | Procédés servant à soulager les symptomes du cancer |
US20060039949A1 (en) * | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
WO2006029406A2 (fr) * | 2004-09-09 | 2006-03-16 | Stryker Corporation | Methodes de traitement de tumeurs osseuses |
-
2006
- 2006-07-29 GB GBGB0615129.4A patent/GB0615129D0/en not_active Ceased
-
2007
- 2007-07-20 WO PCT/GB2007/002755 patent/WO2008015383A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1435243A2 (fr) * | 1998-11-13 | 2004-07-07 | Curis, Inc. | Procédés servant à soulager les symptomes du cancer |
US20060039949A1 (en) * | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
WO2006029406A2 (fr) * | 2004-09-09 | 2006-03-16 | Stryker Corporation | Methodes de traitement de tumeurs osseuses |
Non-Patent Citations (3)
Title |
---|
DATABASE EMBL [Online] WO2003059934 11 March 2004 (2004-03-11), ROSEN C.A. ET AL.: "New albumin fusion proteins useful for preparing a composition for treating diabetes mellitus" XP002474103 retrieved from WWW.EBI.AC.UK accession no. ADH22105 * |
SONG J.J. ET AL.: "Bone morphogentic protein-9 binds to liver cells and stimulates proliferation." ENDOCRINOLOGY, vol. 136, no. 10, 1995, pages 4293-4297, XP002474102 * |
VARADY P. ET AL.: "Morphologic analysis of BMP-9 gene therapy induced osteogenesis." HUMAN GENE THERAPY, vol. 12, 10 April 2001 (2001-04-10), pages 697-710, XP002474101 * |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9138459B2 (en) | 2004-07-23 | 2015-09-22 | Acceleron Pharma Inc. | ACTRIIB-FC polynucleotides, polypeptides, and compositions |
US9163075B2 (en) | 2005-11-23 | 2015-10-20 | Acceleron Pharma Inc. | Isolated polynucleotide that encodes an ActRIIa-Fc fusion polypeptide |
US10239940B2 (en) | 2005-11-23 | 2019-03-26 | Acceleron Pharma Inc. | Method of promoting bone growth by an anti-actriia antibody |
US10071135B2 (en) | 2005-11-23 | 2018-09-11 | Acceleron Pharma Inc. | Method of identifying an agent that promotes bone growth or increases bone density |
US9480742B2 (en) | 2005-11-23 | 2016-11-01 | Acceleron Pharma Inc. | Method of promoting bone growth by an anti-actriia antibody |
US9572865B2 (en) | 2005-11-23 | 2017-02-21 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating multiple myeloma |
US11129873B2 (en) | 2005-11-23 | 2021-09-28 | Acceleron Pharma Inc. | Method for promoting bone growth using activin-actriia antagonists |
US10093707B2 (en) | 2006-12-18 | 2018-10-09 | Acceleron Pharma Inc. | Antagonists of activin-ActRIIa and uses for increasing red blood cell levels |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
US9526759B2 (en) | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
US9399669B2 (en) | 2007-02-02 | 2016-07-26 | Acceleron Pharma Inc. | Variants derived from ActRIIB |
US10259861B2 (en) | 2007-02-02 | 2019-04-16 | Acceleron Pharma Inc. | Variants derived from ActRIIB and uses therefor |
US9353356B2 (en) | 2007-09-18 | 2016-05-31 | Acceleron Pharma Inc. | Activin-actriia antagonists for treating a follicle-stimulating horomone-secreting pituitary tumor |
WO2009084739A1 (fr) * | 2007-12-28 | 2009-07-09 | Kyowa Hakko Kirin Co., Ltd. | Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp10 |
WO2009084738A1 (fr) * | 2007-12-28 | 2009-07-09 | Kyowa Hakko Kirin Co., Ltd. | Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp9 |
US9932379B2 (en) | 2008-08-14 | 2018-04-03 | Acceleron Pharma Inc. | Isolated nucleotide sequences encoding GDF traps |
US10829532B2 (en) | 2008-08-14 | 2020-11-10 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
US11168311B2 (en) | 2008-08-14 | 2021-11-09 | Acceleron Pharma Inc. | Methods for treating anemia in a subject in need thereof |
US9439945B2 (en) | 2008-08-14 | 2016-09-13 | Acceleron Pharma Inc. | Isolated nucleotide sequences encoding GDF traps |
US11162085B2 (en) | 2008-08-14 | 2021-11-02 | Acceleron Pharma Inc. | Methods for treating anemia in a subject in need thereof |
US11155791B2 (en) | 2008-08-14 | 2021-10-26 | Acceleron Pharma Inc. | Methods for treating anemia in a subject in need thereof |
US9505813B2 (en) | 2008-08-14 | 2016-11-29 | Acceleron Pharma Inc. | Use of GDF traps to treat anemia |
US10377996B2 (en) | 2008-08-14 | 2019-08-13 | Acceleron Pharma Inc. | Methods of identifying ActRIIB variants |
US10889626B2 (en) | 2008-08-14 | 2021-01-12 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
US10689427B2 (en) | 2008-08-14 | 2020-06-23 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
US8703927B2 (en) | 2008-08-14 | 2014-04-22 | Acceleron Pharma Inc. | Isolated nucleotide sequences encoding GDF traps |
US10829533B2 (en) | 2008-08-14 | 2020-11-10 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
US8765663B2 (en) | 2009-01-13 | 2014-07-01 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
US9790284B2 (en) | 2009-06-08 | 2017-10-17 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
US10968282B2 (en) | 2009-06-08 | 2021-04-06 | Acceleron Pharma Inc. | Methods for screening compounds for increasing thermogenic adipocytes |
US8703694B2 (en) | 2009-06-08 | 2014-04-22 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
US11066654B2 (en) | 2009-06-12 | 2021-07-20 | Acceleron Pharma Inc. | Methods and compositions for reducing serum lipids |
US9745559B2 (en) | 2009-06-12 | 2017-08-29 | Acceleron Pharma Inc. | Method for decreasing the body fat content in a subject by administering an ActRIIB protein |
US10358633B2 (en) | 2009-06-12 | 2019-07-23 | Acceleron Pharma Inc. | Method for producing an ActRIIB-Fc fusion polypeptide |
US9181533B2 (en) | 2009-06-12 | 2015-11-10 | Acceleron Pharma, Inc. | Truncated ACTRIIB-FC fusion protein |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
US9617319B2 (en) | 2009-11-17 | 2017-04-11 | Acceleron Pharma Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
US10968262B2 (en) | 2009-11-17 | 2021-04-06 | Acceleron Pharma Inc. | Methods of increasing sarcolemmal utrophin |
US9493556B2 (en) | 2010-11-08 | 2016-11-15 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
AU2013243388B2 (en) * | 2012-04-06 | 2018-01-25 | Acceleron Pharma, Inc. | Methods and compositions for increasing red blood cells |
US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
AU2018202326B2 (en) * | 2012-04-06 | 2020-11-26 | Acceleron Pharma, Inc. | Methods and compositions for increasing red blood cells |
US11807673B2 (en) | 2012-04-06 | 2023-11-07 | Acceleron Pharma Inc. | Methods and compositions for increasing red blood cells |
WO2013152213A1 (fr) * | 2012-04-06 | 2013-10-10 | Acceleron Pharma, Inc. | Méthodes et compositions pour l'augmentation des érythrocytes |
US10829534B2 (en) | 2012-04-06 | 2020-11-10 | Acceleron Pharma Inc. | Methods and compositions for increasing red blood cells |
US10344066B2 (en) | 2012-04-06 | 2019-07-09 | Acceleron Pharma Inc. | Methods and compositions for increasing red blood cells |
US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
US11260107B2 (en) | 2014-06-13 | 2022-03-01 | Acceleron Pharma Inc. | Methods and compositions for treating ulcers |
US9850298B2 (en) | 2014-06-13 | 2017-12-26 | Acceleron Pharma Inc. | Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide |
US10487144B2 (en) | 2014-06-13 | 2019-11-26 | Acceleron Pharma Inc. | Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptide |
US11813308B2 (en) | 2014-10-09 | 2023-11-14 | Celgene Corporation | Treatment of cardiovascular disease using ActRII ligand traps |
US11471510B2 (en) | 2014-12-03 | 2022-10-18 | Celgene Corporation | Activin-ActRII antagonists and uses for treating anemia |
US11578110B2 (en) | 2015-08-25 | 2023-02-14 | Histide Ag | Compounds for inducing tissue formation and uses thereof |
WO2017046227A2 (fr) * | 2015-09-17 | 2017-03-23 | Histide Ag | Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique et ses utilisations |
WO2017046227A3 (fr) * | 2015-09-17 | 2017-06-29 | Histide Ag | Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique et ses utilisations |
WO2017046228A3 (fr) * | 2015-09-17 | 2017-06-29 | Histide Ag | Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique, et ses utilisations |
WO2023069447A1 (fr) * | 2021-10-18 | 2023-04-27 | The Uab Research Foundation | Bmp9 ou agoniste de celui-ci et ses utilisations en rapport avec la réduction des métastases du cancer |
Also Published As
Publication number | Publication date |
---|---|
GB0615129D0 (en) | 2006-09-06 |
WO2008015383A8 (fr) | 2009-07-16 |
WO2008015383A3 (fr) | 2008-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008015383A2 (fr) | Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer | |
Yin et al. | Isolation of a Novel Latent Transforming Growth Factor-β Binding Protein Gene (LTBP-3)(∗) | |
Wu et al. | Galectin‐1 promotes choroidal neovascularization and subretinal fibrosis mediated via epithelialmesenchymal transition | |
US10260068B2 (en) | Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva | |
Yi et al. | Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer | |
Van Roeyen et al. | Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D | |
US9708397B2 (en) | Treatment of vasculoproliferative conditions with Lrg1 antagonists | |
Huang et al. | Overexpression of FGF9 in prostate epithelial cells augments reactive stroma formation and promotes prostate cancer progression | |
Kluth et al. | Endothelial expression of CD40 in renal cell carcinoma | |
Miyazaki et al. | Tissue interaction mediated by neuregulin‐1 and ErbB receptors regulates epithelial morphogenesis of mouse embryonic submandibular gland | |
Zhou et al. | Insulin-like growth factor-binding protein-4 inhibits growth of the thymus in transgenic mice | |
JP2017505303A (ja) | 網膜炎症の治療において使用するための薬剤 | |
Querques et al. | Identification of a novel transcription factor required for osteogenic differentiation of mesenchymal stem cells | |
US20050119198A1 (en) | Novel target to inhibit angiogenesis | |
Takehara-Kasamatsu et al. | Characterization of follistatin-related gene as a negative regulatory factor for activin family members during mouse heart development | |
Rampanelli et al. | CD44v3-v10 reduces the profibrotic effects of TGF-β1 and attenuates tubular injury in the early stage of chronic obstructive nephropathy | |
Reneker et al. | Chick δ1-crystallin enhancer influences mouse αA-crystallin promoter activity in transgenic mice | |
Tsou et al. | A novel role for inducible Fut2 in angiogenesis | |
KR20160048103A (ko) | Vegf-c 및 ccbe1의 치료적 용도 | |
Xu et al. | Stromal–epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer | |
US20110312872A1 (en) | Norrin in the treatment of diseases associated with an increased tgf-beta activity | |
Pavelić et al. | Insulin‐like growth factor family in malignant haemangiopericytomas: the expression and role of insulin‐like growth factor I receptor | |
JP5843170B2 (ja) | グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤 | |
Bassing et al. | Receptors for the TGF-β ligand family | |
JP7457331B2 (ja) | 神経膠腫の治療および予防剤、脳腫瘍の悪性度のマーカーおよび脳腫瘍の予後マーカー、脳腫瘍の悪性度および予後の判定方法並びに腫瘍増殖を抑制する抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07766318 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
NENP | Non-entry into the national phase in: |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07766318 Country of ref document: EP Kind code of ref document: A2 |